Home
Products
PROTAC Linker
TOSYL-PROPARGYL-DIETHYLENE GLYCOL > 95 %

TOSYL-PROPARGYL-DIETHYLENE GLYCOL > 95 %

Name: TOSYL-PROPARGYL-DIETHYLENE GLYCOL > 95 %
Brand: BOC Sciences
Rating: 5 (1 reviews)

CAS No.: 1119249-30-7

Cat No.: BP-500105

Purity: 95% 4.5

TOSYL-PROPARGYL-DIETHYLENE GLYCOL is a tosyl-activated propargyl ether derivative of diethylene glycol designed as a versatile PROTAC linker building block. Structurally, it combines a tosyl leaving group with a propargyl handle and a short, flexible diethylene glycol spacer, providing both chemical reactivity and conformational flexibility. In PROTAC synthesis, the tosyl group enables efficient nucleophilic substitution to install the linker onto a nucleophile-bearing targeting ligand or intermediate, while the terminal alkyne (propargyl) supports orthogonal conjugation strategies such as copper-catalyzed azide–alkyne cycloaddition or related click-compatible coupling. The diethylene glycol segment helps maintain linker solubility and can reduce steric constraints between the target-binding and E3 ligase–recruiting modules, which is often critical for preserving ternary complex formation. As a high-purity reagent, it supports reproducible linker assembly and systematic structure–activity studies in targeted protein degradation workflows.

TOSYL-PROPARGYL-DIETHYLENE GLYCOL > 95 %

Structure of 1119249-30-7

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support

Category

PROTAC Linker

Molecular Formula

C14H18O5S

Molecular Weight

298.36

* For research and manufacturing use only. Not for human or clinical use.

Size	Price	Stock	Quantity
--	$--	In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Comprehensive PROTAC Platform
Scientific Expertise & Technical Support
Custom Synthesis & Design Service
Extensive Product Coverage

Cutting-Edge Innovation
Fast Delivery & Global Support
24/7 customer service
100% quality assurance

Popular Publications Citing BOC Sciences Products

Purity

95%

Solubility

In Ethanol: 50 mg/mL (167.59 mM; Need ultrasonic)

Storage

Pure form, -20°C, 3 years; 4°C, 2 years; In solvent, -80°C, 6 months; -20°C, 1 month

Shipping

Room temperature in continental US; may vary elsewhere.

IUPACName

2-(2-prop-2-ynoxyethoxy)ethyl 4-methylbenzenesulfonate

Synonyms

Propargyl-PEG3-Tos;Propargyl-PEG4-Tos

InChI Key

XOLBARIQCXNLPS-UHFFFAOYSA-N

InChI

InChI=1S/C14H18O5S/c1-3-8-17-9-10-18-11-12-19-20(15,16)14-6-4-13(2)5-7-14/h1,4-7H,8-12H2,2H3

SMILES

CC1=CC=C(C=C1)S(=O)(=O)OCCOCCOCC#C

1. Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Haibo Liu, Haiyan Yu, Jun Xia, Ling Liu, Guan J Liu, Hong Sang, Frank Peinemann Meta-AnalysisCochrane Database Syst Rev. 2020 May 1;5(5):CD011368.doi: 10.1002/14651858.CD011368.pub2.

Background:Acne is an inflammatory disorder with a high global burden. It is common in adolescents and primarily affects sebaceous gland-rich areas. The clinical benefit of the topical acne treatments azelaic acid, salicylic acid, nicotinamide, sulphur, zinc, and alpha-hydroxy acid is unclear.Objectives:To assess the effects of topical treatments (azelaic acid, salicylic acid, nicotinamide, zinc, alpha-hydroxy acid, and sulphur) for acne.Search

2. Polyethylene glycol versus lactulose in the treatment of hepatic encephalopathy: a systematic review and meta-analysis

Gilles Jadd Hoilat, Mohamad Fekredeen Ayas, Judie Noemie Hoilat, Ahmed Abu-Zaid, Ceren Durer, Seren Durer, Talal Adhami, Savio John BMJ Open Gastroenterol. 2021 May;8(1):e000648.doi: 10.1136/bmjgast-2021-000648.

Background:Hepatic encephalopathy (HE) is defined as brain dysfunction that occurs because of acute liver failure or liver cirrhosis and is associated with significant morbidity and mortality. Lactulose is the standard of care till this date; however, polyethylene glycol (PEG) has gained the attention of multiple investigators.

3. Effect of Acupuncture in Patients With Irritable Bowel Syndrome: A Randomized Controlled Trial

Lixia Pei, Hao Geng, Jing Guo, Guohui Yang, Lin Wang, Rongrong Shen, Shuyu Xia, Min Ding, Hua Feng, Jin Lu, Jing Li, Lian Liu, Yanye Shu, Xiangdong Fang, Xiaoliang Wu, Xiaoxiao Wang, Shengjie Weng, Lu Ju, Xiao Chen, Hong Shen, Jianhua Sun0 Mayo Clin Proc. 2020 Aug;95(8):1671-1683.doi: 10.1016/j.mayocp.2020.01.042.Epub 2020 Jun 1.

Objective:To evaluate the effect and safety of acupuncture for the treatment of irritable bowel syndrome (IBS) through comparisons with those of polyethylene glycol (PEG) 4000 and pinaverium bromide.Patients and methods:This multicenter randomized controlled trial was conducted at 7 hospitals in China and enrolled participants who met the Rome III diagnostic criteria for IBS between May 3, 2015, and June 29, 2018. Participants were first stratified into constipation-predominant or diarrhea-predominant IBS group. Participants in each group were randomly assigned in a 2:1 ratio to receive acupuncture (18 sessions) or PEG 4000 (20 g/d, for IBS-C)/pinaverium bromide (150 mg/d, for IBS-D) over a 6-week period, followed by a 12-week follow-up. The primary outcome was change in total IBS-Symptom Severity Score from baseline to week 6. Results:Of 531 patients with IBS who were randomized, 519 (344 in the acupuncture group and 175 in the PEG 4000/ pinaverium bromide group) were included in the full analysis set. From baseline to 6 weeks, the total IBS-Symptom Severity Score decreased by 123.51 (95% CI, 116.61 to 130.42) in the acupuncture group and 94.73 (95% CI, 85.03 to 104.43) in the PEG 4000/pinaverium bromide group. The between-group difference was 28.78 (95% CI, 16.84 to 40.72; P<.001). No participant experienced severe adverse effects.Conclusion:Acupuncture may be more effective than PEG 4000 or pinaverium bromide for the treatment of IBS, with effects lasting up to 12 weeks.Trial registration:Chinese Clinical Trials Register, ChiCTR-IOR-15006259.

ConcentrationVolumeMass	1 mg	5 mg	10 mg
1 mM	3.3518 mL	16.7588 mL	33.5177 mL
5 mM	0.6704 mL	3.3518 mL	6.7035 mL
10 mM	0.3352 mL	1.6759 mL	3.3518 mL

This TOSYL-PROPARGYL-DIETHYLENE GLYCOL linker is a tosyl-activated propargylated diethylene glycol building block designed for efficient conjugation in PROTAC synthesis. Its activated leaving group supports robust functionalization, while the propargyl handle enables subsequent click-compatible coupling strategies. Researchers can use this reagent to assemble targeted protein degraders with modular linker architectures, improving synthetic flexibility and enabling systematic exploration of linker length and chemistry; detailed structural and reactivity considerations are provided below.

Structure: The molecule contains a tosyl (p-toluenesulfonyl) sulfonate ester functionality attached to a propargyl position, connected through a diethylene glycol ether chain. It features aromatic sulfonyl bonding, alkyne and ether linkages, and a polar, flexible polyether segment that can enhance solubility and conformational adaptability.

Reactivity: The tosyl group serves as an excellent leaving group under nucleophilic substitution conditions, facilitating installation of the propargyl functionality onto other PROTAC fragments. In typical PROTAC linker workflows, the alkyne moiety is then used for copper-free or copper-mediated azide–alkyne cycloaddition, following established click chemistry principles. Commonly used solvents include polar aprotic media, with base or nucleophile selection tailored to the coupling partner and desired chemoselectivity.

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂